PMID- 17099820
OWN - NLM
STAT- MEDLINE
DCOM- 20061213
LR  - 20061113
IS  - 1439-4421 (Electronic)
IS  - 0941-3790 (Linking)
VI  - 68
IP  - 10
DP  - 2006 Oct
TI  - [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: 
      development and cost-of-illness analysis].
PG  - 600-12
AB  - PURPOSE: Obesity and type 2 diabetes mellitus (T2 DM) among children have 
      increased in the last years and developed into a major public health problem in 
      Germany. Obesity and T2 DM are important causes of morbidity among young people 
      associated with high costs for the health system. The objective of this paper is 
      to estimate the number of obese and diabetic children and adolescents and the 
      associated economic burden of illness in Germany now (2003) and in the future. 
      METHODS: Cost assessments of obesity in adulthood and studies of obese children 
      in Germany are based on English and German scientific publications and internet 
      sources. Cost calculations are based on the top-down approach and the prevalence 
      method. Direct costs of illness are derived from aggregate statistical data (ICD 
      10: obesity E 65-68; T2 DM E 11) and various scientific publications and 
      telephone interviews. Except for T2 DM, other comorbidities of obesity are 
      neglected in this analysis. RESULTS: In 1999, 1.3 million children were 
      overweight and 594,000 were obese in Germany. The highest prevalence of obesity 
      was in children aged 14 to 17 years. The prevalence for overweight children has 
      risen from 8.9 % to 15.7 % and for obese children from 10.1 % to 13.1 % over the 
      period from 1994 to 1999/1998. Approximately 1 % of these were type 2 diabetics. 
      During 2003, the mean annual direct costs of obesity were euro 44 million, with 
      euro 36.4 million for rehabilitation, euro 3.6 million for hospital care and euro 
      3.9 million for special medical programs. The costs of juvenile T2 DM were euro 
      1.4 million (hospital care and rehabilitation). Mean costs per treated obese 
      child added up to euro 3484.00 and to euro 8539.00 per treated obese child with 
      T2 DM. The incremental costs are euro 2489.00 for obese children and euro 7544.00 
      for obese children with T2 DM compared to the average costs of illness of a child 
      aged 5 to 20 years in Germany. Future annual attributable costs of obesity could 
      be up to euro 6.4 million, 7.3-10.1 % of all obesity costs and for T2 DM up to 
      euro 17.3 million (without T2 DM comorbidities) and euro 92.1 million (inclusive 
      of all T2 DM comorbidities), 7.0-55.6 % of all obesity costs. CONCLUSIONS: 
      Obesity and T2 DM are rapidly emerging as major disorders of childhood and 
      adolescence and as important cost drivers for the health system. Due to the lack 
      of data, there is a need for further research in the costs of obesity and T2 DM 
      among children and for studies on suitable interventions to obviate a major 
      public health crisis in Germany. The challenge for health policy is to identify 
      effective and efficient prevention strategies.
FAU - Wolfenstetter, S B
AU  - Wolfenstetter SB
AD  - GSF-Forschungszentrum fur Umwelt und Gesundheit--Institut fur Gesundheitsokonomie 
      und Management im Gesundheitswesen, Neuherberg, Germany.
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Adipositas und die Komorbiditat Diabetes mellitus Typ 2 bei Kindern und 
      Jugendlichen in Deutschland: Entwicklung und Krankheitskostenanalyse.
PL  - Germany
TA  - Gesundheitswesen
JT  - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes 
      (Germany))
JID - 9204210
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Comorbidity
MH  - *Cost of Illness
MH  - Diabetes Mellitus, Type 2/*economics/*epidemiology
MH  - Female
MH  - Germany/epidemiology
MH  - Health Care Costs/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Obesity/*economics/*epidemiology
MH  - Prevalence
MH  - Risk Assessment/*methods
MH  - Risk Factors
EDAT- 2006/11/14 09:00
MHDA- 2006/12/14 09:00
CRDT- 2006/11/14 09:00
PHST- 2006/11/14 09:00 [pubmed]
PHST- 2006/12/14 09:00 [medline]
PHST- 2006/11/14 09:00 [entrez]
AID - 10.1055/s-2006-927181 [doi]
PST - ppublish
SO  - Gesundheitswesen. 2006 Oct;68(10):600-12. doi: 10.1055/s-2006-927181.